We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close


Lowenstein FDA Chair Eyes Biosimilar Battles, Off-Label Rules

Law360 (August 10, 2018, 4:33 PM EDT) -- Lowenstein Sandler LLP’s James Shehan, chair of the firm’s U.S. Food and Drug Administration practice, tells Law360 he's tracking patent litigation over biosimilars, watching for new off-label promotion policies and eyeing innovative approaches to clinical trials.

James Shehan Shehan, who joined Lowenstein two years ago in its New York City office, has a resume that includes in-house stints as general counsel at Novo Nordisk and corporate counsel at Pfizer Inc.

He has also been in private practice at FDA boutique Hyman Phelps & McNamara PC, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.